期刊文献+

唑来膦酸治疗女性绝经后骨质疏松所致急性发热临床分析 被引量:19

Analysis of acute fever reaction in postmenopausal women with zoledronic acid treatment for osteoporosis
下载PDF
导出
摘要 目的分析静脉用唑来膦酸治疗女性绝经后骨质疏松患者引起的急性发热反应及其相关因素。方法回顾性分析我科2010年6月至2012年4月使用静脉用唑来膦酸5mg治疗的绝经后骨质疏松患者共63人。观察急性期发热出现比例。按是否出现发热症状分为发热组与无发热组。比较两组患者年龄、静脉用唑来膦酸治疗前骨质疏松严重程度、甲状旁腺激素、血清钙差异,及治疗前使用抗骨质疏松药物差异。结果 63例患者中共观察到21例发热,占33.3%。71%(15/21)的患者治疗当天出现发热,于患者均为次日出现发热。66.7%(14/21)的患者发热持续1天,5例发热持续2天,发热时平均体温(38.8±0.5)℃。发热组与无发热组比较,发热组治疗前甲状旁腺激素水平显著高于无发热组(P值<0.05);骨质疏松严重程度、血清钙两组无显著差异。结论绝经后骨质疏松患者静脉用唑来膦酸治疗时出现急性期发热反应并不少见,但均为一过性。治疗前PTH水平与发热相关。 Objective To analyze the incidence of acute fever reaction after the treatment of intravenous zoledronic acid in postmenopausal women with osteoporosis, and to identify the related factors. Methods Clinical data of 63 postmenopausal women with osteoporosis, who were treated with intravenous infusion of 5mg zoledronic acid from June 2010 to April 2012, were analyzed retrospectively. The incidence of acute fever reaction in these patients was observed. All the patients were divided into fever group and non-fever group according to whether having fever symptoms or not. The age, severity of osteoporosis before zoledronic acid treatment, variations of parathyroid hormone and serum calcium, and the use of anti-osteoporosis drugs before the treatment were compared between the 2 groups. Results Twenty-one patients had acute fever reaction (33.3%). Among these 21 patients, 71% patients (15/21) had fever on the day of zoledronic acid treatment, and the other patients had fever on the first day after the treatment. The fever lasted for 1 day in 66.7% of the patients ( 14/21 ) , and for 2 days in 5 patients. The average temperature was 38.8 ± 0. 5C. The patients with fever had higher parathyroid hormone level before treatment than those without fever (P 〈 0.05). Serum calcium and bone mineral density showed no significant difference between the 2 groups. Conclusion Acute fever reaction is not rare in postmenopausal patients receiving intravenous zoledronic acid for the treatment of osteoporosis, but it is transient. Parathyroid hormone level before the treatment is associated with the fever.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2013年第1期58-60,共3页 Chinese Journal of Osteoporosis
关键词 静脉用唑来膦酸 骨质疏松 急性期发热反应 Intravenous zoledronic acid Osteoporosis Acute fever reaction
  • 相关文献

参考文献10

  • 1吕靖,马彩玲.绝经后骨质疏松症的治疗新进展[J].医学综述,2007,13(1):62-63. 被引量:37
  • 2Coxon FP, Helfrich MH, Vant Hof RJ, et al. Protein geranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphanates and GGTI-298 [ J ]. J Bone Miner Res ,2000,15 ( 8 ) : 1467-1476.
  • 3崔巍,彭六保.唑来膦酸的临床应用研究进展[J].中南药学,2006,4(6):467-469. 被引量:19
  • 4Coleman R, Burkinshaw R, Winter M, et al. Zoledronic acid [ J ]. Expert Opin Drug Saf,2011 (1) :133-145.
  • 5Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6 [ J ]. J Interferon Cytokine Res,2003,23 ( 11 ) :649-654.
  • 6Bertoldo F,Pancheri S, Zenari S, et al. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion [ J ]. J Bone Miner Res ,2010,25 ( 3 ) :447-454.
  • 7邓海鸥,李东风,张伟杰,智喜梅,许翎,吴文.静脉用唑来膦酸治疗老年骨质疏松患者时引起的急性期发热反应分析[J].南方医科大学学报,2011,31(12):2076-2078. 被引量:22
  • 8Reid IR, Gamble GD, Mesenbrink P, et al. Characterization of and risk factors for the acute-phase response after zoledronic acid [ J ]. J Clin Endocrinol Metab, 2010, 95(9) :4380-4387.
  • 9楼永海,赵云.骨质疏松症的药物治疗概况[J].海峡药学,2006,18(6):88-90. 被引量:4
  • 10Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatm ent of postmenopausal osteoporosis [ J ]. N Engl Med,2007,356 (18) : 1809-1822.

二级参考文献59

  • 1杨玲,殷晓进.锶与骨矿代谢[J].中国骨质疏松杂志,2004,10(3):384-387. 被引量:17
  • 2[1]Skerjance A,Berenson J,Hsu C,et al.The Pharmacokinetics and harnacodynemics of Zoledronic Acid in Cancer Patients with varying Degrees of Renal Function[J].J Clin Pharmacol,2003,43 (2):154-162.
  • 3[2]Croucher P,Jagdev S,Coleman R.The anti-tumor potential of zoledronic acid[J].Breast,2003,12 (2):30-36.
  • 4[3]Body JJ.Clinical research update:Zoledronic[J].Cancer,1997,15 (8):1699-1701.
  • 5[4]Mundy GR,Yoneda T,Hiraga T.Preclinical studies with zoledronic acid and other bisphosphonates:impact on the bone microenvironment[J].Semin oncol.2001,28 (4):35-44.
  • 6[7]Major PP,Coleman RE.Zoledronic acid in treatment of hypercalcemia of malignancy:Results of the international clinical development program[J].Semin oncol,2001,289 (2 Suppl 6):17-19.
  • 7[8]Major P,Lortholary A,Hon J,et al.Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy:a pooled analysis of two randomized,cont rolled clinical t rials[J].J Clin Oncol,2001,19 (2):558-567.
  • 8[9]Reid IR,Brown JR,Burckhard P,et al.Intravenous Zoledronic acid in postmenopausal women with low bone mineral density[J].N Engl J Med,2002,346 (9):653-656.
  • 9[10]Rosen LS,Gordon D Kaminskim,et al.Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma:a phase Ⅲ,double-blind,comparcative trial[J].Cancer J,2001,Sep 31; 7 (5):377-387.
  • 10[11]Rosen LS,Gordon D,Tchek Medyian S,et al.Long-Term efficacy and safety of Zoledronic acid compared with pamidronate disodium in the treatment of skeletal complication in patients with advanced multiple or breast carcinoma:a randomized,double-blind,multicenter,comparative trial[J].Cancer,2003,98 (8):1735-1744.

共引文献76

同被引文献163

  • 1李敬会,蔡莉莉,李德梅.唑来膦酸治疗老年骨质疏松症临床分析[J].实用老年医学,2013,27(9):777-778. 被引量:13
  • 2刘斌,戎利民,谢沛根,等.PVP联合唑来膦酸治疗绝经后骨质疏松性椎体骨折的疗效分析[C].中华医学会骨科学分会微创学组2011年年会论文集,2011:264-271.
  • 3Blasco J, Martinez-Ferrer A, Macho J,et al.Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures : a 12-month randomized follow-up, controlled trial [J]. J Bone Miner Res, 2012,27 (5):1159- 1166.
  • 4Harrop JS, Prpa B, Reinhardt MK, et al. Primary and secondar osteoporosis incidence of Subsequent vertebral compression Fractures after kyphoplasty [ J ]. Spine, 2004,29 (19) : 2120-2125.
  • 5Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis [J]. N Engl J Med, 2007,356 ( 18 ) : 1809-1822.
  • 6Eidtmann H, de Boer H, Bundred N, et al. Efficacy of zohdmnie acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:36-month results of the ZO- FAST Study [ J ]. Ann Oneol, 2010,21 ( 11 ) : 2188-2194.
  • 7McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in thetreatment of postmenopausal women with low bone density previously treated with alendronate [J]. Bone, 2007,41 ( 1 ) : 122-128.
  • 8Freitas-Neto CA,De Oliveira Fagundes WB,Ribeiro M Jr,et al.Unilateral Uveitis with Vitreous Haze Follow ing Zoledronic Acid Therapy for Osteoporosis[J].Semin Ophthalmol,2013,22(29):68-80.
  • 9Kachnic LA,Pugh SL,Tai P,et al.randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients[J].Prostate Cancer Prostatic Dis,2013,16(4):382-386.
  • 10Rossini M,Zanotti R,Viapiana O,et al.Zoledronic Acid in Osteoporosis Secondary to M astocytosis[J].Am J M ed,2014,3(19):9340-9343.

引证文献19

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部